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Abstract
Background—Pseudoxanthoma elasticum (PXE) is a heritable ectopic mineralization disorder
affecting cutaneous, ocular and cardiovascular systems, caused by mutations in the ABCC6 gene.
PXE presents with a marked clinical and genetic heterogeneity. Furthermore, heterozygous
carriers may present with limited histopathological features. This study was conducted to
investigate a patient with PXE and her family members clinically, histopathologically, and
genetically.
Methods—Clinical and histopathological examinations and mutation analyses of ABCC6 gene
were performed.
Results—Lesional skin biopsy of the PXE patient demonstrated clumping and fragmentation of
elastic fibers, and calcification in the dermis. Non-lesional axillary skin samples of the husband,
daughter and older son were histopathologically normal. The skin from similar region of a
younger son revealed elastic fibers with some fragmentation, clumping, but no mineralization. The
PXE patient was homozygous for the R1141X mutation in the ABCC6 gene. The husband had wild
type alleles, while all children were heterozygous carriers. Daily treatment of antioxidant therapy
with tocopherol acetate and ascorbic acid was prescribed to the PXE patient. After one year, both
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clinical and histopathological regression of the lesions was observed, however, lesions began to
progress during additional six months period of treatment.
Conclusion—The mutation analyses of ABCC6 gene are important to determine the genotype of
both PXE patients and putative heterozygous carriers, since histopathological features of carriers
may differ even in the same family. The role of antioxidant therapy for PXE is unclear, and there
is a need for controlled clinical trials.
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INTRODUCTION
Pseudoxanthoma elasticum (PXE) is a heritable ectopic mineralization disorder affecting
cutaneous, ocular and cardiovascular systems, caused by mutations in the ABCC6 gene. The
characteristic cutaneous findings, yellowish papules or plaques on the lateral sides of the
neck and flexural sites of the body, are associated with inelastic, leathery skin. The diagnosis
is confirmed by histopathological examination of a skin biopsy demonstrating calcification
of pleiomorphic elastic fibers (1-3). PXE presents with a marked clinical and genetic, both
intraand inter- familial heterogeneity. Furthermore, some patients with minimal or absent
cutaneous findings and heterozygous carriers may present difficulties in diagnosis (2).
PXE is an autosomal recessively inherited disorder, and the mutated gene, ABCC6, is
located on chromosome 16p13.1 (4, 5). Up until now, over 300 distinct mutations in the
ABCC6 gene have been defined, the R1141X mutation being the most common one detected
in Caucasians (6). The function of the ABCC6 protein has yet to be identified, but it has
been proposed that it serves as a efflux transporter, and that mutations in the ABCC6 gene
lead to deficiency of circulating anti-mineralization factors, thus allowing ectopic
mineralization, with associated complications to ensue (2, 7). In this study, a patient with
PXE and her family members from Turkish population were investigated clinically,
histopathologically and genetically for the first time to provide additional insight into PXE.
METHODS
Clinical evaluation of patients
A 47-year-old woman presented to the out-patient clinic with cosmetically disturbing skin
lesions around her neck and with blurred vision. Neither her parents nor she and her husband
were consanguineous. She had a 27-year-old daughter and two sons aged 26 and 10 years.
No one except the proband complained about similar skin lesions. Detailed dermatological,
physical, ophthalmological, and cardiological examinations were performed on all family
members.
Histopathological examinations
A skin biopsy from the lesional skin of the proband and biopsies from the normal appearing
skin of axillary sites of all children and the husband were obtained after informed consent.
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The specimens were embedded in paraffin and then examined according to routine
procedures, in which hematoxylin and eosin, von Kossa, and elastic stains were employed.
ABCC6 gene mutation analysis
After informed consent, DNA samples for mutation analyses of the ABCC6 gene were
performed in all family members. Genomic DNA was isolated from peripheral blood
samples (QIAamp Blood Maxi kit; Qiagen Inc., Valencia, CA). PCR was performed using
2.0 U Taq polymerase and Q buffer (Qiagen), according to the manufacturer's instructions.
PCR reactions contained 200 ng DNA as template and 20 ng of each primer in a final
volume of 50 µl. The entire coding region and intron/exon boundaries of ABCC6 were
amplified using PCR primers as described previously (6). For the detection of the deletion of
exons 23–29, the primers described by Le Saux et al (8) were used. The PCR products were
analyzed with direct sequencing using an Applied Biosystems 3730 Sequencer (Applied
Biosystems, Foster City, CA). In the ABCC6 gene, the +1 corresponds to the A nucleotide in
the ATG translation initiation codon (GenBank accession no. AF076622).
RESULTS
Clinical features of the subjects
The proband had ~10 years history of asymptomatic plaques consisting of multiple
yellowish papules, a few millimeters in diameter over her lateral neck regions and nape (Fig.
1a). She had hypertension and blurred vision for the past two years. Her fundoscopic
examination revealed angioid streaks (Fig. 1b). She denied abnormal hemorrhages or
claudication. Laboratory tests, including complete blood count, liver and renal function tests,
calcium x phosphate product, lipid profile, and urine analysis were all within normal limits.
Fecal occult blood test was negative. Chest X-ray, electrocardiogram (ECG),
echocardiogram (ECHO), abdominal ultrasonography, and cranial magnetic resonance
imaging did not show abnormal findings. The dermatological, ophthalmological, and
cardiovascular examinations, and laboratory tests, ECHO and ECG evaluations of other
family members were all normal, and no angioid streaks were detected.
Histopathology
Skin biopsy taken from the lateral neck of the proband demonstrated clumping and
fragmentation of elastic fibers, and calcification in the dermis (Fig. 2a-c). While the biopsy
from the skin of the 10 year-old son revealed no mineralization (Fig. 2d, e), elastic fibers
with special stain showed some fragmentation and clumping (Fig. 2f). Histopathological
examination of skin samples from the non lesional axillary regions of the husband (not
shown), 27-year-old daughter and 26-year-old son (Fig. 2g-i and Fig. 2j-l) were normal.
Mutations of ABCC6 gene
The nuclear pedigree of the family is shown in Fig. 3a. DNA analysis demonstrated that the
proband (I-2) was homozygous for the R1141X mutation. The husband (I-1) had arginine
(R) at the amino acid position 1141 in both alleles (wild type), while all children of the
proband were found to be heterozygous carriers for the R1141X mutation (Fig. 3b).
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Based on clinical, histopathological and genetic examinations, the proband was diagnosed as
having PXE with three major criteria, including characteristic yellowish skin lesions in
flexural sites, elastic fiber calcification in lesional skin, and presence of ocular findings (1).
The younger son, a carrier of the R1141X mutation, was considered to have mild
histopathological alterations associated with PXE, but he had no evidence of clinical
disease. The other children, who were also heterozygous carriers of the R1141X mutation,
had normal histopathology of the skin and no clinical findings suggestive of PXE.
Management of the subjects
The proband was advised to have yearly cardiological examination, close monitoring of the
eye complications, avoidance of non-steroidal anti-inflammatory drugs and warfarin, and
oestrogens and hormone replacement therapy. She was recommended to have regular
exercise without contact sport, weight control, and avoid smoking. In addition to these
recommendations, daily treatment with 150 IU of tocopherol acetate and 1000 mg of
ascorbic acid was prescribed. Within the first year of follow up period, the papules appeared
to regress (Fig. 1c), and clinically there was no significant further deterioration of
fundoscopic findings. During the treatment, all laboratory tests remained within normal
limits and no adverse effects were noted.
To determine the histopathological response to the above therapy, a second biopsy specimen
was taken from the lesional skin, just near the scar of the first biopsy; one year after the
therapy was initiated. The histopathological examination suggested less clumping and
fragmentation of elastic fibers and calcification in the dermis (Fig. 4a, b). However, no
improvement was detected in fundoscopic examination and vision. The patient continued the
therapy for an additional year, but she subsequently discontinued the treatment since the
skin lesions were found to progress again during the last six months of the therapy.
DISCUSSION
The current PXE classification categorizes patients depending on clinical and
histopathological findings (Tables 1 and 2) (1). According to this classification scheme, the
proband in our study was in category I with three major features. The two older children had
normal elastic fibers without calcification; similar with the histopathological features in the
father who had the wild type ABCC6 gene, and detection of only one mutant allele
established that they were heterozygous, clinically unaffected carriers of PXE. These
findings point the importance of presymptomatic testing in the families of patients with PXE
since there is a lack of carrier phenotypes. The youngest child, a 10-year-old boy, had
fragmented and clumped elastic fibers without calcification. It has been suggested that
abnormally structured elastic fibers without calcification may be seen at the early stages of
the disease or they may be a feature of the heterozygous patients (9-11). Until now,
however, there have been only a few studies investigating the histopathological
characteristics of skin in heterozygotes (9, 11, 12). Before the identification of ABCC6 as the
mutated gene in PXE, the study by Bacchelli et al (9) found increased elastin and elastic
fiber polymorphism in 18 asymptomatic, putative heterozygote family members as
compared to healthy controls, but the changes were less pronounced than in patients with
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PXE. A few of these individuals had also areas of mild mineralization. Martin et al (11)
examined skin biopsies of seven PXE patients’ relatives confirmed to be heterozygotes by
mutation analysis of ABCC6. In these patients, increased amounts of short, thick and
fragmented elastic fibers were detected. Besides, foci of abnormal elastic tissue
mineralization were also found. The abnormal elastic fiber morphology in carriers of a
single ABCC6 mutation was suggested of having a phenotype midway between the wild type
and homozygote skin. Subsequently, Plomp et al (12) reported detailed analyses of 15
homozygous and 41 heterozygous cases and 12 healthy controls. Increased elastin was
reported in 63% and fragmentation of elastic fibers in 57% of heterozygous individuals’
skin, while no clumping or calcification was seen. The percentages of these findings were
higher in homozygous cases. Upon these findings, the authors suggested that an increase and
fragmentation of elastin in the skin of heterozygotes may not be a reliable criterion to
differentiate them from homozygous patients. Although our study includes only three
heterozygous carriers, the data may add information to our knowledge about PXE.
Specifically, the histopathologic features in one of the carriers in our study revealed short,
thick and fragmented elastic fibers without mineralization, findings consistent with the
previous studies. It remains to be investigated why only one of the three heterozygous
carriers demonstrated pathology of elastic fibers and the others did not. One reason may be
the site selection for normal appearing skin. Axillary region is generally preferred for this
kind of investigation in PXE, since biopsy from this site of skin is cosmetically acceptable,
and it is not affected by external factors, such as ultraviolet radiation that alters the elastic
fibers in the dermis (13). Nevertheless, future studies investigating other sites, such as
inguinal area, may help to diagnose heterozygous carriers, in which skin biopsy may be a
diagnostic tool to obtain clues of PXE.
The current classification system of PXE is based on major and minor criteria that describe
the skin findings, histopathology with calcification and fragmentation of elastic fibers,
family history of PXE in first-degree relatives, and presence of angioid streaks (Tables 1 and
2) (1). Category I is considered to represent definitive PXE. However, the clinical evaluation
of an individual may not always allow the diagnosis to be made, since the expression of
PXE phenotype is of late onset and often not present in younger individuals (1, 2). Typical
skin and eye findings are usually noted in adulthood, while angioid streaks are rarely
detected before the age of ten (12). Histopathological findings may also vary from one
patient to another, together with variable clinical findings (1, 9, 11, 12). Elastic fiber
calcification of the non-lesional skin is one of the minor criteria; on the other hand,
calcification may not be demonstrable in about 20% of PXE patients (12). Category II
represents patients with tentative diagnosis but it is often unclear whether they are
heterozygous carriers or they will develop typical findings of PXE later in life (1). This
uncertainty of the value of histopathological changes in the skin in heterozygous carriers
emphasizes the importance of DNA-based mutation analysis in the ABCC6 gene. It should
be noted, however, that the most commonly employed mutation detection strategies which
amplify exons and flanking intronic sequences of the ABCC6 gene from genomic DNA, may
not detect all mutations, including those in the regulatory regions or in intronic sequences
away from intron-exons junctions, or large allelic deletions (6, 8).
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Early identification and accurate diagnosis of PXE, homozygous or compound heterozygous
for ABCC6 mutations, as well as of the heterozygous carriers, is important for several
reasons. First, accurate and early diagnosis of definitive PXE allows institution of
appropriate monitoring of complications and measures to counteract the development of the
disease. Secondly, while the heterozygous carriers do not develop the characteristic
cutaneous findings of PXE, carriers of ABCC6 mutations, particularly the R1141X, have
been suggested to be at risk for premature coronary artery disease (13, 14). These
considerations are emphasized by the phenotypic heterogeneity that is noted in patients with
PXE, even within the same family. This phenotypic variability has been suggested to reflect
the influence of genetic modifier genes as well as the lifestyle and dietary variables in these
patients.
It is clear that mutations in the ABCC6 gene underlie PXE in the classic form of PXE,
however, the pathomechanistic details leading from ABCC6 mutations into peripheral
ectopic mineralization of connective tissues remain unclear (3). The role of oxidative stress
has been suggested to play a role in modifying the PXE phenotype. For example,
intracellular reactive oxygen species have been reported to be high in fibroblasts cultured
from the skin of patients with PXE, and the total antioxidant status was lower in PXE
fibroblasts as compared to the controls (15, 16). In this context, Zarbock et al, (17) have
detected polymorphisms in antioxidant genes associated with altered enzyme activity of
CAT, GPX1, and SOD2 in patients with early clinical manifestation of the symptoms.
Addition of vitamin E to fibroblasts from patients with PXE has been shown to reverse the
oxidative stress (16). Based on these and similar observations, it has been suggested that
antioxidant therapy might improve the presentation of patients with PXE, and a study by
Takata et al, (18) has suggested that administration of tocopherol and ascorbic acid may
improve the appearance of the skin lesions in PXE. Depending on these observations, we
administered the proband an antioxidant therapy consisting of 150 IU of tocopherol and 1 g
of ascorbic acid daily. It appeared that the skin lesions may have regressed over the initial 18
month period of treatment, but thereafter the lesions appeared to progress again. These
outcomes may suggest that antioxidant therapy could suppress the oxidant
microenvironment of the skin for a certain time period but may not be effective for long
term maintenance. Furthermore, it is not clear as to the optimal dose of these agents. It
should also be noted that the treatment of Abcc6−/− mice, an animal model of PXE, failed to
counteract the mineralization (19). Specifically, although it was shown that these mice
suffered from chronic oxidative stress, diet including vitamins C and E, selenium, and N-
acetylcysteine did not prevent the progression of the ectopic mineralization. Thus, the role of
antioxidant therapy for PXE is unclear, and there is a need for controlled clinical trials for
patients with PXE.
Quite recent studies have demonstrated the effectiveness of oral phosphate binders and diet
enriched in magnesium in counteracting the calcium deposition in PXE mice (20-22).
Specifically, supplementation of the normal mouse diet with 5-fold higher amount of
magnesium completely prevented the mineralization, but did not reverse the existing mineral
deposits. Preliminary clinical trials have also suggested that phosphate binders and
magnesium may be helpful for treatment of patients with PXE (23, 24). These observations,
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if applicable to larger cohorts of patients in future clinical trials, would suggest that such
treatment should be considered for PXE and should be initiated as soon as the diagnosis has
been established.
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Figure 1.
Clinical findings in the family with PXE. (a) Plaques of multiple yellowish papules over the
neck of the proband with PXE; (b) The patient has angioid streaks (arrows) as observed by
fundoscopic examination; (c) Regression of the skin lesions of the patient with PXE after
one year duration of antioxidant therapy.
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Figure 2.
Histopathology of the skin in the proband (a-c), , in the clinically unaffected son who is
heterozygous carrier with pathologic elastic fibers (d-f), and in the normal heterozygous
older siblings (g-i and j-l). (2a, d, g, j: H&E, x200; 2b, e, h, k: von Kossa, x100;2c, f, i, l:
elastic stain, x200).
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Figure 3.
Family pedigree (a), and mutation analysis demonstrating the presence of R1141X mutation
(b). The proband (I-2; arrow) is homozygous for the mutation, while the husband of the
proband (I-1) shows wild type sequence, R1141. The three children (II-1,2,3) are
heterozygous carriers of the mutation.
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Figure 4.
Less calcification (a) and elastic fibers (b) in the second biopsy of first patient, when
compared with the first biopsy. (4a: H&E, x100; 4b: elastic stain, x400)
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Table 1
Criteria for the diagnosis of PXE.
Major criteria
    1. Characteristic skin involvement
    2. Characteristic histopathologic features of lesional skin
    3. Characteristic ocular disease in adults older than 20 years of age
Minor criteria
    1. Characteristic histopathologic features of nonlesional skin
    2. Family history of PXE in first-degree relatives
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Table 2
Classification of PXE*
Category I (3 major
criteria)
Category IIa (1 major+2
minor criteria)
Category IIb (1 major
+1 minör criteria)
Category IIc (1 major
+1minor criteria)
Category IId (2
minor criteria)
1. Characteristic yellow
skin lesions in flexural
sites
1. Angioid streaks 1. Angioid streaks 1. Angioid streaks 1. Family history of
PXE in first-degree
relatives
2. Elastic fiber
calcification-lesional
skin
2. Elastic fiber calcification-
nonlesional skin
2. Elastic fiber
calcification-nonlesional
skin
2. Family history of PXE
in first-degree relatives
2. Elastic fiber
calcification-
nonlesional skin
3. Ocular disease in
adults
3. Family history of PXE in
first-degree relatives
*Adopted from reference 1.
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